RR-MS patients and healthy controls showed similar circulating levels of EGF and MIP-1β/CCL4 (EGF: 87±71 vs 115±92; MIP-1β/CCL4: 141±79 vs 170±116) and progressive patients had significantly lower levels of EGF and MIP-1β/CLL4 than HC (EGF: 50±54 vs 115±92, p<0.0001 and MIP-1β/CCL4: 93±67 vs 170±116, p = 0.0002, respectively). This evidence concerns the gene EGF and myeloid sarcoma.